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Abstract 
Background: Erratic tacrolimus blood levels are associated with liver and kidney graft failure.  We 
hypothesized that erratic tacrolimus exposure would similarly compromise lung transplant outcomes. This 
study assessed the effect of tacrolimus mean and standard deviation (SD) on the risk of chronic lung 
allograft dysfunction (CLAD) and death after lung transplantation.  
 
Methods: We retrospectively reviewed all lung transplant recipients who received tacrolimus based 
immunosuppression (n=110). Cox proportional hazard modeling was used to investigate the effect of 
tacrolimus mean and SD on survival and CLAD. At census 48 (44%) patients had developed CLAD and 37 
(34%) were deceased.  
 
Results: Tacrolimus SD was highest for the first six post-transplant months (median (IQR) 4.01 (3.04-4.98)) 
before stabilising at 2.84 (2.16-4.13) between 6-12 months. The SD then remained the same (2.85 (2.00-
3.77) between 12-24 months. A high mean tacrolimus level 6-12 months post-transplant independently 
reduced the risk of CLAD (HR 0.74 (0.63-0.86), p<0.001) but not death (HR 0.96 (0.83-1.12), p=0.65).  In 
contrast, a high tacrolimus SD between 6-12 months independently increased the risk of both CLAD (HR 
1.46 (1.23-1.73), p<0.001) and death (HR 1.27 (1.08-1.51), p=0.005).  
 
Conclusions: Erratic tacrolimus levels are a risk factor for poor lung transplant outcomes. Identifying and 
modifying factors which contribute to this variability may significantly improve outcomes.  
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Background 
Chronic loss of allograft function is the major cause of morbidity and mortality after transplantation and its 
prevention rightly remains one of the main focuses of post-transplant care. In the lung, this process is now 
termed chronic lung allograft dysfunction (CLAD) and is characterised by a permanent 20% decline in FEV1 
over the best achieved post-transplant.  CLAD is associated with reduced quality of life and increased 
mortality following lung transplantation (1-6). Acute rejection remains the most important risk factor (7).  
 
The currently available immunosuppressive agents (typically a corticosteroid, a cell cycle inhibitor and a 
calcineurin inhibitor) are generally very effective at preventing the development of acute rejection if 
therapeutic drug levels can be reached (6, 8-10). Of these agents, cyclosporine led to the biggest step-
change in the success of solid organ transplantation, with more recent evidence supporting a slight 
advantage for tacrolimus over cyclosporine in lung transplantation (11-16). 
 
Therapeutic drug monitoring of tacrolimus trough levels is essential to achieve adequate 
immunosuppression while minimising toxicity. While the mean drug level required to prevent rejection has 
been well studied, little attention has been paid to the effect of erratic tacrolimus exposure, but with a 
satisfactory mean, in lung transplantation (15, 17-22). There are good reasons to believe that erratic 
exposure may be just as deleterious as sub-therapeutic tacrolimus exposure, but this possibility has been 
little explored. High tacrolimus trough level variability (assessed using standard deviation (SD)) increases 
the risk of acute rejection early post adult lung transplant but its affect on CLAD and survival are unknown 
(23). In the liver and kidney transplant literature, an association has been found between high intra-patient 
tacrolimus level variability and late graft failure (24-26). This has not been assessed in adult lung transplant 
recipients. We aimed to assess the effect of mean tacrolimus trough level as well as variation in tacrolimus 
trough levels, assessed using SD, on the development of CLAD and survival following adult lung 
transplantation. We also aimed to identify factors which influence tacrolimus trough level variability. 
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Methods 
A retrospective review was performed of the medical records of patients who underwent lung 
transplantation at our centre between 1996 and 2013 and had received tacrolimus for at least the first year 
post-transplant. Those patients prescribed cyclosporine after the first 6 months were excluded. Almost all 
(97%) patients were prescribed twice-daily tacrolimus. Our centre has been using basiliximab routinely for 
induction therapy and tacrolimus as the preferred calcineurin inhibitor since April 2011.  Prior to this 
cyclosporine was the preferred calcineurin inhibitor with tacrolimus reserved for patients experiencing 
refractory acute rejection while receiving cyclosporine, or (in females) excessive hair growth.  Azithromycin 
has been used for prevention of BOS since April 2009. The practice of vaccination, antibiotic and antifungal 
use did not alter.  No changes in prescription of corticosteroids, cell cycle inhibitors or timing of surveillance 
biopsies (week 3, 6, 12 and months 6 and 12) were made during the study period.  There were no changes 
in tacrolimus management over the study period. Tacrolimus oral dose was given (commencing dose of 
0.15 mg/kg/day, target trough level 5-15 ug/l) in two divided doses, one hour before or two hours after 
food. Target trough levels were 5-15 g/l (10-15 g/l for 0-6 months followed by 5-10 g/l from 6 months).  
Individual target ranges varied, taking into account history of rejection, infection and other side-effects, but 
not pre-transplant diagnosis. Tacrolimus dose adjustments for CF patients were made as for the non-CF 
cohort. Oral pancreatic enzyme replacement was provided to those CF patients with pancreatic 
insufficiency. Tacrolimus monitoring was performed 3 times/week for the first 2 weeks post transplant, 
then twice weekly for 4 weeks, weekly for 1 month and then fortnightly for 1 month.  For patients with 
stable levels further blood draws were performed monthly up until 6 months and then 3 monthly 
thereafter. Levels were checked 3-4 days following tacrolimus dose adjustments and twice weekly for 
inpatients.  
 
Collected data included patient demographics, date of transplant, time post-transplant or date of death, 
disease indication for transplant, type of transplant and tacrolimus blood trough levels.  Acute rejection 
burden was assessed by summing the A grades in the first 12 months. CLAD was defined as a 20% fall from 
best post-transplant FEV1 as per the evolving International Society of Heart and Lung Transplant (ISHLT) 
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guidelines (27).  Respiratory function tests were performed at 2 weeks post transplant and then twice 
weekly for 4 weeks, weekly for 1 month, fortnightly for 1 month and then 3 monthly thereafter. Patients 
performed daily home spirometry and were instructed to present to clinic if they had a reduction of 10%. 
Tacrolimus trough levels were measured as part of routine post transplant care in both inpatients and 
outpatients by two pathology providers using liquid chromatography-tandem mass spectrometry (LC-MS) 
or immunoassay (Abbott ARCHITECT, EMIT 2000), with good correlation shown between the methods (28).  
The mean and SD tacrolimus trough level was determined for each subject in each of the 0-6 month, 6-12 
month and 12-24 month post-transplant epochs.  The study was approved by the Prince Charles Hospital 
Human Research and Ethics Committee.  
 
Data was analysed using Stata v11 (StataCorp, TX, USA) and a p-value <0.05 was considered statistically 
significant. The results are presented as median (interquartile range).  The time from transplant to CLAD or 
death was modeled using Cox proportional hazard regression.  Potential predictors included demographic 
factors (sex, age at transplant, donor type (cardiac or brain death), transplant type, indication for 
transplant), clinical factors (use of induction therapy, sum of A grades, PGD grades) and tacrolimus mean 
trough levels and tacrolimus SD over the time periods as stated.  The final model was obtained by forwards 
and backwards selection, retaining covariates where inclusion or exclusion changed the coefficients of 
other predictors by more than 10% or where predictors were statistically significant at α=0.05.  Simple and 
multivariate linear regressions were performed with tacrolimus SD as the dependent variable. Simple linear 
regression analysis was initially used to evaluate the relationship between variables and SD and those 
variables in which p<0.1 were then subjected to multiple linear regression analysis. 
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Results 
Cohort Characteristics 
110 subjects, median age 41.3 (IQR 27.6 – 51.6) years were included.  Table 1 displays the baseline 
characteristics. 56% of subjects were female, 87% had bilateral transplants, and the indications for 
transplant were cystic fibrosis (CF, 47%), chronic obstructive pulmonary disease (COPD, 26%), pulmonary 
fibrosis (8%) and other (21%). Median follow up was 60 (30.6-95.7) months. At census 37 patients (34%) 
were deceased and 48 (44%) had developed CLAD.   
 
Tacrolimus Mean and SD 
Tacolimus SD was 4.01 (3.04 – 4.98), 2.84 (2.16 – 4.13) and 2.85 (2.00-3.77) for the 0-6, 6-12 and 12-24 
month epochs, respectively (Figure 1). Since the tacrolimus SD was similar for the 6-12 and 12-24 month 
epochs (p=0.73), we chose to use the 6-12 month epoch for all further analyses. During this time, there 
were 33 patients who had tacrolimus levels measured while an inpatient, however there was no difference 
in the standard deviation of inpatient versus outpatient tacrolimus levels (data not shown). The mean 
tacrolimus level for the 6-12 month epoch was 9.8 (8.56 – 10.75) g/L and showed a moderate correlation 
with SD over the same period (rho=0.360, p<0.001, Figure 2). There was no relationship found between the 
sum of A grade rejection (1 month, 6 month or 12 month cumulative) and either the 0-6 month or 6-12 
month SD. As there was a long study period, we analysed the mean and standard deviation between those 
transplanted before and including 2005 (n=48) and those transplanted from 2006 onwards (n=62). We 
found no difference between either the tacrolimus mean or standard deviation between the two groups 
(data not shown).  
 
The median number of tacrolimus measurements per patient for the 0-6, 6-12 and 12-24 month periods 
were 15 (IQR 8 – 24), 11 (7-17, range 2-30 measurements) and 13 (7-20) respectively. There was a positive 
correlation between the number of tacrolimus measurements and trough level SD (r = 0.489 p<0.001, 
Figure 3) but not with the mean (p=0.698).  
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Predictors of Tacrolimus SD 
Neither the 6-12mth mean tacrolimus level nor the standard deviation were associated with demographic 
factors, the sum of A grade rejection, transplant type or disease indication (including a diagnosis of cystic 
fibrosis, Supplementary Table 1). 
 
Predictors of CLAD and death 
No demographic factors were associated with CLAD or death, however a history of acute rejection 
increased the risk of both CLAD and death (Table 2 and 3). Mean tacrolimus levels from 6-12 months were 
negatively associated with CLAD on both univariate (Hazard Ratio (HR) 0.85 (95% Confidence Interval (CI) 
0.74 – 0.99), P=0.032) and multivariate analysis (HR 0.74 (CI 0.63 – 0.86), P<0.001, Table 2), but not with 
survival (Table 3). Tacrolimus SD from 0-6 months was not a predictor of CLAD (HR=1.07 CI 0.96-1.21 
p=0.227), but tacrolimus SD from 6-12 months was independently associated with time to CLAD (HR 1.46, 
CI 1.23 – 1.73, P<0.001, Table 2) and death (HR 1.27, CI 1.08 – 1.51, P=0.005, Table 3). For each 1 unit 
increase in the tacrolimus standard deviation, the risk of CLAD and death was increased by 46% and 27% 
respectively.  In order to exclude the possibility that inpatients, who may be sicker and also have more 
tacrolimus blood draws perhaps thus affecting the SD, may confound our findings, we repeated the analysis 
after excluding tacrolimus levels taken from inpatients. Even after excluding these levels, tacrolimus SD 
from 6-12 months remained a strong independent predictor of time to CLAD (HR 1. 57, CI 1.29 – 1.93, 
P<0.001) and death (HR 1.36, CI 1.09 – 1.70, P=0.006).  
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Discussion 
In this retrospective, single-centre cohort study we found that both lower mean and higher standard 
deviation of tacrolimus levels, assessed between 6 and 12 months post-transplant, independently 
predicted time to the development of CLAD, with the standard deviation also predicting mortality.   
 
Identifying those patients most at risk of developing chronic rejection and premature death post transplant 
is one of the key challenges facing treating physicians. This study is important as it is the first to assess the 
effect of tacrolimus trough level variability on the incidence of CLAD or survival in the setting of adult lung 
transplantation. While much attention is paid to the attainment of satisfactory tacrolimus levels after 
transplant, little attention is paid to the variability of those levels. We postulate that patients with 
fluctuating tacrolimus trough levels are more likely to have levels outside of the therapeutic range 
predisposing them to immune mediated rejection, toxicity (including nephrotoxicity) and infection. These 
findings are clinically relevant since tacrolimus SD is simple to calculate and predicts subsequent graft loss 
and mortality, providing an opportunity for this new knowledge to rapidly translate into better graft and 
patient outcomes in a highly cost-effective manner. Our results suggest that at the end of the first post-
transplant year, assessing the tacrolimus SD may identify patients with erratic levels who are at high risk for 
subsequent CLAD and/or death.  
 
The first 6 months post transplant is often complicated by more frequent use of high dose steroids (for 
acute rejection), triazole antifungal prophylaxis and gastrointestinal factors (including gastroparesis) which 
may affect absorption or metabolism of tacrolimus. These difficulties are reflected in the high tacrolimus 
level SD during this period. However our data suggest that the erratic tacrolimus exposure during this 
period does not impact on long term outcomes. In this respect, the 6-12 month period was found to be 
particularly important as a high tacrolimus SD during this period both predicted a persistently high SD in the 
second post-transplant year and poor outcome. Collectively our data suggest that there are a subgroup of 
individuals who have persistently high variability in tacrolimus levels across the life of their transplant and 
that these individuals could be readily identified before their outcome is compromised.  
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Our work expands on previous studies that have looked for an association between tacrolimus level SD and 
acute rejection in adult lung transplant recipients as well as chronic rejection and graft failure in other solid 
organ transplants.  We found no association between acute rejection and tacrolimus SD.  Chiang et al, on 
the other hand, found a 23% increase risk of acute rejection for each 1 unit rise in tacrolimus trough level 
SD in the first 8-90 days post transplantation (23). In adult kidney transplant recipients, high within patient 
variability in tacrolimus clearance (estimated by correcting the blood trough level for the oral dose) in the 
6-12 month period was found to increase the risk of graft failure and rejection after 12 months (24). 
Further, Pollock-BarZiv’s group assessed tacrolimus level variability using SD in paediatric solid organ 
(including 15 lung) transplant recipients finding a threshold of 2 SD, above which there was increased risk 
of late rejection and graft loss (26). Venkat et al also found a 2 SD threshold above which there was an 
increased risk of late rejection in their paediatric liver transplant cohort (29). We chose to assess our 
standard deviation data as a continuous variable and found that for each one unit increase in SD, the time 
to CLAD or death increased by 46% and 27% respectively, implying that even small increases in SD can 
adversely affect outcome. 
 
There are a multitude of factors which may cause highly variable tacrolimus trough levels beyond the early 
post-transplant period. For a given patient, the oral bioavailability of tacrolimus can vary greatly from dose 
to dose (30). One particular group of interest are those with CF who have a unique gastrointestinal 
pathology with significant risk of variability in absorption. Chiang et al proposed that tacrolimus absorption 
may affect tacrolimus level SD in those with CF. In their cohort of 99 lung transplant recipients (<3 months 
post transplant), those that developed acute rejection had higher pre-rejection tacrolimus level SD and 
were made up of a higher proportion of patients with CF (23). However, our findings did not reflect this, 
with no association between indication for transplant, or indeed any demographic factor, and tacrolimus 
variability, CLAD or survival. Given that poor adherence to post-transplant care is well known to 
compromise outcomes, we believe it is likely that poor adherence to the prescribed tacrolimus dosing 
schedule will explain at least some of the variability in tacrolimus exposure in our cohort. Non-adherance to 
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the dose, the dosing interval, the requirement to take tacrolimus without food, or the timing of blood 
draws could all contribute to increased tacrolimus SD. In this respect, tacrolimus SD may be an excellent 
surrogate not only for tacrolimus exposure, but also the ability and/or willingness to follow relatively 
complicated medical advice. Although adherence is generally high in lung transplant recipients, poor 
adherence has been shown to be associated with a greater tacrolimus level SD in liver transplant recipients 
(25, 31). The relationships between tacrolimus SD, more conventional measures of adherence, and 
transplant outcomes will be a key focus of future studies.   
 
Pharmacogenomic factors may play a role in determining tacrolimus level mean but little consideration has 
been paid to its effect on intra-patient variability. Previous studies have found that gene polymorphisms, 
particularly in CYP3A5, affect tacrolimus concentration-dose relationships, so predicting initial dose 
requirements in lung transplant recipients (32-34). In kidney transplant recipients, a polymorphism of 
CYP3A5 was found to be a risk factor for acute rejection and nephrotoxicity (35). Single nucleotide 
polymorphism analysis of 240 Chinese kidney transplant recipients has revealed a number of other 
polymorphisms affecting tacrolimus metabolism (36). Another future direction in lung transplantation may 
involve SNP analysis to identify patients more susceptible to variable tacrolimus levels or low mean, 
possibly improving preoperative risk stratification and outcomes.  
 
Variable or reduced exposure to other medications may provide an alternate explanation for the 
association between tacrolimus SD, CLAD and survival. Other medications (including concurrently 
prescribed immunosuppressants) are often affected by similar factors including adherence, absorption and 
metabolism.   While it is possible, indeed likely, that high tacrolimus SD acts as a surrogate for variable 
exposure to other medication, most of the other commonly prescribed drugs have a wider therapeutic 
window so that variability in drug exposure may be expected to have less of an impact on long-term 
outcome. Indeed in the study by Borra et al there was no association between variability in mycophenolate 
clearance and graft failure (24). 
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We believe it is likely that our findings will be able to be generalized to other lung transplant cohorts since 
our cohort’s characteristics are similar to those in most transplant centres, except for a slightly higher 
proportion of patients transplanted for CF.  However we do acknowledge some limitations. Given the 
retrospective design of the study, the timing of tacrolimus levels post dose may have varied, thus 
potentially affecting both SD and mean.  However, the ‘real-world’ nature of a retrospective study will 
capture this kind of variability, which in itself may be an important measure of the patient’s ability to 
ensure accurate timing of blood draws, and to follow other relatively complicated, but vital, components of 
post-transplant care. Although there were some changes in transplant protocols during the 17-year study 
period (specifically the introduction of basiliximab induction and azithromycin prophylaxis) these agents are 
not known to significantly alter tacrolimus metabolism (37). Furthermore we saw no era effect when we 
specifically tested the possibility that historical changes in transplant practice may systematically alter 
tacrolimus SD or mean. The correlation between number of tacrolimus measurements and trough level SD 
is an uncontrolled potential confounder. It is possible that more frequent assessment of levels in sicker 
patients resulted in more frequent dose adjustment with increased variability. However when inpatients 
(often sicker, having more frequent levels) were removed from the analysis, the SD and mean were not 
substantially different, and tacrolimus SD still predicted CLAD and death. In fact the relationship between 
medical monitoring and scheduling of blood draws on adherence to the prescribed tacrolimus schedule is 
likely complex and potentially unpredictable. For instance it is possible that less adherent, sicker patients 
may take medications reliably only immediately prior to blood draws thus increasing variability. Conversely 
one could envisage a different outcome, with adherence and variability improving with more frequent 
levels as individuals improve behaviour in response to their awareness of being observed (the Hawthorne 
Effect). However, perhaps the most obvious mode of confounding – that a non-adherent patient at risk of 
poor outcome may undergo fewer blood tests and therefore have a higher SD - can be excluded since 
tacrolimus SD was a positive function of the number of observations. In summary, although we believe the 
observed association between high tacrolimus SD and poor outcome is robust, our study does not provide 
insight into potential mechanisms. 
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In conclusion, patients with highly variable trough tacrolimus levels in the second half of the first post-
transplant year will likely have similar variability in the second year and are at high risk for subsequent 
CLAD and death.  Calculating the tacrolimus SD, identifying those with a high SD, and modifying factors 
contributing to it would seem pertinent objectives at the one year post-transplant anniversary.  Specifically 
targeting these individuals to identify and correct any factors which may be contributing to erratic levels 
may significantly improve their outcome and survival. 
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Figure Legends 
Figure 1: Standard deviation of tacrolimus trough levels at various times post transplantation. Data are 
presented as box and whiskers plot  
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Figure 2: Standard deviation versus mean tacrolimus level 6-12 months post transplant.  
r=0.36, p<0.001 
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Figure 3: Standard deviation versus number of tacrolimus measurements from 6-12 months post 
transplant.  r=0.49, p<0.001 
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Table 1 Cohort characteristics 
Total cohort Total cohort 
(n=110) 
CLAD-free  
(n=62) 
CLAD 
(n=48) 
P value 
Female sex, n (%) 62 (56%) 37 (60) 25 (52) 0.445 
Tx type, n (%) 
Bilateral Sequential Lung Tx 
Single Lung Tx 
Heart/Lung Tx 
Heart/Lung/Liver Tx 
 
96 (87%) 
3 (3%) 
7 (6%) 
4 (4%) 
 
56 (90) 
0 (0) 
3 (5) 
3 (5) 
 
40 (84) 
3 (6) 
4 (8) 
1 (2) 
0.164 
Tx indication, n (%) 
Cystic fibrosis 
COPD 
Idiopathic pulmonary fibrosis 
Other 
 
52 (47%) 
28 (26%) 
9 (8%) 
21 (19%) 
 
32 (51) 
13 (21) 
6 (10) 
11 (18) 
 
20 (42) 
15 (31) 
3 (6) 
10 (21) 
0.529 
Tx age, median (IQR) years 41.3 (27.6 – 51.6) 38.9 (27.5-20.5) 44.0 (29.2-52.4) 0.816 
CLAD at census, n (%) 48 (44) 0 (0) 48 (100)  
Deceased, n (%) 37 (34) 5 (8) 32 (67) <0.001 
Time to CLAD, median (IQR) 
months 
35.0 (21.3 – 69.4)  35.0 (21.3 – 69.4) 
 
Time to death, median (IQR) 
months 
54.5 (31.8 – 90.8) 20.3 (18.6-41.6) 59.7 (40.2-95.1) 0.037 
Total follow-up time, median 
(IQR) months 
60 (30.6 – 95.7) 45.0 (26.2-79.8) 70.3 (41.9-112.5) 0.004 
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Table 2: Factors associated with time to CLAD following transplantation 
 HR (95% CI) P value 
Univariate   
Mean 6-12mth 0.85 (0.74 – 0.99) 0.032 
SD 6-12mth 1.25 (1.08 – 1.45) 0.003 
Acute rejection grade (cumulative 0-12mths) 1.14 (1.02 – 1.29) 0.026 
   
Multivariate   
Mean 6-12mth 0.74 (0.63 – 0.86) <0.001 
SD 6-12mth 1.46 (1.23 – 1.73) <0.001 
Acute rejection grade (cumulative 0-12mths) 1.13 (1.00 – 1.28) 0.058 
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Table 3: Factors associated with time to death following transplantation 
 HR (95% CI) P value 
Univariate   
SD 6-12mth 1.29 (1.09 – 1.53) 0.002 
Acute rejection grade (cumulative 0-12mths) 1.25 (1.09 – 1.43) 0.001 
   
Multivariate   
SD 6-12mth 1.27 (1.08 – 1.51) 0.005 
Acute rejection grade (cumulative 0-12mths) 1.24 (1.08 – 1.43) 0.002 
 
 
